Comparing the current results to its competitors, Century Therapeutics Inc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 5.1 %, recorded in the same quarter.
Century Therapeutics inc , slower than the average decrease reported by the company's competitors of -20.18 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -20.18 %
Century Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industry, focusing on novel immunotherapies for cancers and autoimmune disorders. It faces competition from large and specialty pharmaceutical, biopharmaceutical, and biotechnology companies, as well as academic research institutions and governmental agencies. The company holds non-exclusive licenses from FCDI and Inscripta, Inc. for certain patent portfolios related to iPSC technology and genetic engineering, respectively. These non-exclusive licenses allow third parties to obtain rights to the same patents, potentially increasing competition. The company recognizes that competitors may develop product candidates more rapidly or effectively, which could impact its ability to develop and commercialize products.
June 3, 2024
Century Therapeutics, a leading cell therapy company, has presented promising interim results from their Phase 1 ELiPSE-1 study at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO). The results highlight the safety and efficacy of CNTY-101, a cutting-edge investigational cell therapy for the treatment of hematologic malignancies.During the ongoing dose escalation phase of the study, CNTY-101 has demonstrated a manageable safety profile. Importantly, no dose-limiting toxicities (DLTs) or graft-versus-host disease (GvHD) have been observed in the patients enrolled. Moreover, a majority of the patients have been treated in an outpatient setting, further emphasizing the potential feasib...
Philadelphia-based biotechnology company Century Therapeutics Inc. recently presented initial data from the CNTY-101 Phase 1 ELiPSE-1 trial at the 65th ASH Annual Meeting. The results highlight the potential for a multi-dosing strategy for CAR iNK therapy enabled by allo-evasion edits. In addition, the therapy was found to be generally well tolerated in a high-risk, heavily pretreated patient with refractory or relapsed B-cell lymphoma, at Dose Level 1 (100 million cells). Century Therapeutics Inc. is emerging as a leader in developing innovative technologies to address cancer and degenerative diseases. CAR iNK therapy, one of their flagship programs, utilizes induced pluripotent stem cells (iP...
Pluri Inc's business model revolves around providing digital solutions and services to various clients. They leverage their expertise and technology to offer customized software development, IT consulting, and digital marketing services. With a focus on delivering tailored solutions, Pluri Inc aims to meet the specific needs and goals of their clients and support their growth in the digital landscape.
Nkgen Biotech Inc is a biotechnology company that focuses on developing and commercializing innovative cell therapies for the treatment of various diseases. Their business model involves conducting extensive research to identify and isolate specific cells capable of addressing medical conditions, followed by developing manufacturing processes to produce these cells in large quantities. They aim to partner with healthcare providers and pharmaceutical companies to ensure the effective distribution and delivery of their therapies to patients in need.
Sources:
Century Therapeutics inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Century Therapeutics inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
